# A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct07258407/  
OnCo record `nct07258407` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TD001 in prostate cancer, run by T.O.A.D. Oncology SA, now recruiting.

## Summary

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07258407 by T.O.A.D. Oncology SA, with 180 participants planned, started 2026-01-30 and due to reach its primary completion in 2028-03. Interventions recorded: TD001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07258407
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer
- Sponsor: T.O.A.D. Oncology SA
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07258407: https://clinicaltrials.gov/study/NCT07258407

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct07258407.json